We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Foundation Medicine, Inc. (delisted) | NASDAQ:FMI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 137.00 | 136.95 | 136.95 | 0 | 00:00:00 |
From Jan 2020 to Jan 2025
By Pietro Lombardi
Roche Holding AG (ROG.EB) and Foundation Medicine Inc. (FMI) reached a definitive merger agreement Tuesday, under which Roche will acquire all the outstanding shares in Foundation Medicine not already owned by Roche and its affiliates for $2.4 billion.
Roche said that it will pay $137 per share in cash, which represents a premium of 29% to Foundation Medicine's closing price on Monday. The deal values the company at $5.3 billion.
"This is important to our personalized healthcare strategy as we believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments. We will preserve FMI's autonomy while supporting them in accelerating their progress," Daniel O'Day, chief executive of Roche Pharmaceuticals, said.
Roche expects to close the transaction in the second half of 2018.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
June 19, 2018 01:42 ET (05:42 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Foundation Medicine, Inc. Chart |
1 Month Foundation Medicine, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
